Close

Top Drug Patent Losses in 2018

January 24, 2018    


PBA Health has compiled a list of the top drug patent losses slated to take effect during 2018. These brand patent expirations would open the door for generic versions of these products to launch.

“All generic launches are estimates and are contingent upon approval from the Food and Drug Administration (FDA),” said Mark Waltrip, Manager of Trade Relations at PBA Health.

Check back here for updates about new products in the PBA Health warehouse, including brands, generics and OTCs.

The following drugs have patents set to expire in 2018 and are organized by expiration date. (Adapted from this list on lowestmed.com.)

Here are the top drug patent losses expected in 2018


1. Follistim®
(Follitropin beta)
Patent Expiration Date: Jan. 14, 2018

2. Spiriva®
(Tiotropium)
Patent Expiration Date: Jan. 30, 2018

3. Makena®
(Hydroxyprogesterone)
Patent Expiration Date: Feb. 3, 2018

4. Astepro®
(Azelastine)
Patent Expiration Date: Feb. 20, 2018

5. Sensipar®
(Cinacalcet)
Patent Expiration Date: March 8, 2018

6. Adipra®
(Insulin glulisine)
Patent Expiration Date June 18, 2018

7. Lexiva®
(Fosamprenavir)
Patent Expiration Date: June 24, 2018

8. Tekturna®
(Sliskerin)
Patent Expiration Date: July 21, 2018

9. Tekturna® HCT
(Aliskren and hydrochlorothiazide tablets)
Patent Expiration Date: July 21, 2018

10. Tikosyn®
(Dofetilide)
Patent Expiration Date: Oct. 9, 2018

11. Promacta®
(Eltrombopag)
Patent Expiration Date: Oct. 30, 2018

12. Levitra®
(Vardenafil)
Patent Expiration Date: Oct. 31, 2018

13.Staxyn®
(Vardenafil)
Patent Expiration Date: Oct. 31, 2018

14. Fortesta®
(Testosterone)
Patent Expiration Date: Nov. 9, 2018

15. Symbicort®
(Budesonide/formoterol)
Patent Expiration Date: Nov. 11, 2018

16. Tyvaso®
(Treprostinil)
Patent Expiration Date: Nov. 13, 2018

17. Finacea®
(Azelaic acid)
Patent Expiration Date: Nov. 18, 2018

18. VESIcare®
(Solifenacin)
Patent Expiration Date: Nov. 19, 2018

19. Pradaxa®
(Dabigatran)
Patent Expiration Date: Nov. 20, 2018